Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized PatientsBenzinga • 04/11/22
Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming EfficacyGlobeNewsWire • 04/11/22
Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer ConferenceGlobeNewsWire • 03/04/22
Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022GlobeNewsWire • 03/01/22
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers SymposiumGlobeNewsWire • 02/17/22
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as PlannedGlobeNewsWire • 02/14/22
Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/09/22
Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%GlobeNewsWire • 02/09/22
Can Veru Inc. (VERU) Climb 344% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 02/08/22
Earnings Preview: Veru Inc. (VERU) Q1 Earnings Expected to DeclineZacks Investment Research • 02/02/22
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 TrialGlobeNewsWire • 02/01/22
Veru Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress SyndromeGlobeNewsWire • 01/31/22
Veru to Report Fiscal 2022 First-Quarter Financial Results, Host Conference Call on February 9thGlobeNewsWire • 01/26/22
Veru to Present Corporate Update at the H.C. Wainwright BioConnect Conference on January 10-13, 2022GlobeNewsWire • 01/03/22
Veru Announces FDA Approval of ENTADFI, a New Treatment for Benign Prostatic HyperplasiaGlobeNewsWire • 12/13/21
Veru Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer SyGlobeNewsWire • 12/08/21
Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 12/02/21